The "remote switch" allows CAR-T cells to learn to "balance work and rest."

The research team composed of the Ludwig Cancer Research branch in Lausanne and the Swiss Federal Institute of Technology in Lausanne has designed a new method to regulate CAR-T cells on demand. The latest issue of the journal Nature Chemical Biology reported on the design and preclinical evaluation of these novel CAR-T cells, demonstrating their effectiveness and controllability in mouse cancer models. This advancement lays the foundation for expanding such powerful tools to more complex scenarios, such as solid tumor therapy in the future, and is expected to benefit more patients from this precise immunotherapy.